Valeant Pharmaceuticals International Inc

Valeant Pharmaceuticals International — Corporate Update (March 2006)

21 slides from Valeant Pharmaceuticals International's corporate update, Mar 21, 2006

  1. Slide 1: Valeant Pharmaceuticals International

    _VVALEANT armaceuticals International

  2. Slide 2: Viramidine Safety and Efficacy Versus Ribavirin VISER1 (first of two Phase 3 studies)

    VIramidine Safety and Efficacy Versus Ribavirin VISER1 (first of two Phase 3 studies)

  3. Slide 3: VISER1 Summary

    VISER1 Summary Confirms superior safety profile Clear dose response based on weight Higher concentrations of Viramidine do not result in proportional increases in anemia Regional anomalies influenced results

  4. Slide 4: Viramidine Phase 3 (VISER1) Study: Design

    Viramidine Phase 3 (VISER1) Study: Design Randomized, Double-blind Multicenter, Parallel-group Study in Treatment-naive Subjects (N = 970) 24 weeks of follow-up 24/48 weeks of treatment* Screening (30 days) Randomization (2:1) Follow-up Ribavirin 1000/1200 mg/QD + PegIntron† Viramidine 600 mg BID +

  5. Slide 5: Co-Primary Endpoints

    Co-Primary Endpoints Primary safety endpoint: Hemoglobin < 10 g/dL or ^ 2.5 g/dL drop from baseline Superiority test vs. ribavirin Primary efficacy endpoint: Sustained Virologic Response - HCV RNA < 100 copies/mL at FW 24 Non-inferiority test vs. ribavirin

  6. Slide 6: Superiority in Safety Confirmed

    Superiority in Safety Confirmed

  7. Slide 7: Safety: Anemia Incidence Hgb <10 g/dL Anytime During Therapy

    Safety: Anemia Incidence Hgb <10 g/dL Anytime During Therapy Overall Safety Population Viramidine (FD) Ribavirin (WBD) SVR 0.05 0.23 5% 24% N = 324 N = 646 P<0.0001

  8. Slide 8: Efficacy influenced by: Compliance, Regional anomalies, Weight-based dosing

    Efficacy influenced by: Compliance (per protocol) Regional anomalies Weight-based dosing

  9. Slide 9: Efficacy influenced by: Compliance, Regional anomalies, Weight-based dosing

    Efficacy influenced by: Compliance (per protocol) Regional anomalies Weight-based dosing

  10. Slide 10: Per Protocol Population (PP)

    Per Protocol Population (PP) Completed protocol specified treatment duration ^ 23 weeks for GT 2,3 ^ 47 weeks for GT non 2,3 Had overall study drug exposure of ^90% for both components of the combination therapy Did not have therapy interruption ^15 days Did not receive any prohibited con-meds (e.g.

  11. Slide 11: Viramidine Efficacy Analysis: Sustained Virologic Response

    Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.53 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.62 0.56 0.6 0.53 38% 52% 62% 52% N=646 N=421 N=324 N=216 (-0.002, 0.151) 95% CI for Difference of Proportion (0.072, 0.194) ITT PP

  12. Slide 12: Efficacy influenced by: Compliance, Regional anomalies, Weight-based dosing

    Efficacy influenced by: Compliance (per protocol) Regional anomalies Weight-based dosing

  13. Slide 13: Sustained Virologic Response Overall by Region (PP)

    Sustained Virologic Response Overall by Region (PP) NA EU NA/EU ROW Viramidine (FD) 0.54 0.48 0.51 0.56 Ribavirin (WBD) 0.57 0.54 0.55 0.78 54% 57% 48% 55% 55% 78% 56% 51% 95% CI for Difference of Proportion * Meets non-inferiority criteria N=168 N=100 N=159 N=62 N=327 N=162 N=94 N=54 ? (-0.060, 0.1

  14. Slide 14: Viramidine Efficacy Analysis: Sustained Virologic Response

    Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.53 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.62 0.56 0.6 0.53 38% 52% 51% 56% 62% 52% N=646 N=421 N=324 N=216 N=327 N=162 95% CI for Difference of Proportion (-0.060, 0.118) * (-0.002, 0.151) * Meets non-inferiority criteri

  15. Slide 15: Efficacy influenced by: Compliance, Regional anomalies, Weight-based dosing

    Efficacy influenced by: Compliance (per protocol) Regional anomalies Weight-based dosing

  16. Slide 16: Viramidine Weight Based Analysis Overall (PP)

    Viramidine Weight Based Analysis Overall (PP) Sustained Virologic Response Anemia: <10 g/dL Viramidine mg/kg Viramidine mg/kg <18 19-22 >23 East 0.48 0.64 0.81 47% N=323 66% N=82 81% N=16 <18 19-22 >23 East 0.043 0.024 0.125 2% N=82 4% N=323 12.5% N=16

  17. Slide 17: Sustained Virologic Response Overall Weight Strata NA & EU (PP)

    Sustained Virologic Response Overall Weight Strata NA & EU (PP) <=75kg >75kg Viramidine (FD) 0.622 0.419 Ribavirin (WBD) 0.6 0.533 62% 60% 42% 53% 95% CI for Difference of Proportion (-0.034, 0.213) (-0.177, 0.079) * N=148 N=70 N=179 N=92 * Meets non-inferiority criteria

  18. Slide 18: Viramidine Efficacy Analysis: Sustained Virologic Response

    Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.53 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.62 0.56 0.6 0.53 38% 52% 51% 56% 62% 52% 62% 60% 42% 53% N=646 N=421 N=324 N=148 N=70 N=92 N=179 N=216 N=327 N=162 95% CI for Difference of Proportion (-0.060, 0.118) * (-0.177,

  19. Slide 19: VISER1 Summary

    VISER1 Summary Confirms superior safety profile Clear dose response based on weight Higher concentrations of Viramidine do not result in proportional increases in anemia Regional anomalies influenced results

  20. Slide 20: Viramidine Path to Market

    Viramidine Path to Market VISER1 Presentation at Scientific Meeting - 1H06 VISER2 Follow-up Completed - End of June 2006 VISER2 Analyses Completed - 2H06 VISER2 Presentation at Scientific Meeting - 4Q06; 1Q07 Market Availability - Before End of 2007

  21. Slide 21: Valeant Pharmaceuticals International

    _VVALEANT armaceuticals International

Valeant Pharmaceuticals International — Corporate Update (March 2006) on 6ix